Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial
Spyros Chalkias, Patrick Dennis, Dena Petersen, Krishnakumar Radhakrishnan, Leroy Vaughan, Reem Handforth, Alexandra Rossi, Rahnuma Wahid, Darin K. Edwards, Jing Feng, Weiping Deng, Honghong Zhou, Elizabeth de Windt, Verónica Urdaneta, Yamuna Devi Paila, Bethany Girard, Saul N. Faust, Stephen R. Walsh, Catherine A. Cosgrove, Jacqueline M. Miller, Rituparna Das
Topics & Concepts
ImmunogenicityVirologyMedicineCoronavirus disease 2019 (COVID-19)Double blindMessenger RNAPlaceboBiologyImmunologyAntibodyGeneInternal medicineGeneticsAlternative medicinePathologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches